These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 321170)

  • 1. The therapeutic equivalence of oral and intravenous iron in renal dialysis patients.
    Strickland ID; Chaput de Saintonge DM; Boulton FE; Francis B; Roubikova J; Waters JI
    Clin Nephrol; 1977 Feb; 7(2):55-7. PubMed ID: 321170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of oral iron in dialysis patients.
    Strickland ID; Chaput de Saintonge DM; Boulton FE; Brain AJ; Goodwin FJ; Marsh FP; Zychova Z
    Clin Nephrol; 1974; 2(1):13-7. PubMed ID: 4595978
    [No Abstract]   [Full Text] [Related]  

  • 3. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
    Ahsan N
    Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral or parenteral iron therapy in haemodialysis patients?
    Winney RJ; Swainson CP; Parker AC; Bone JM; Robson JS
    Proc Eur Dial Transplant Assoc; 1977; 14():184-91. PubMed ID: 600955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anemia in chronic hemodialysis; comparative value of iron therapy administered by oral and intravenous routes].
    Ducros J; Benas P; Salvadori JM; Olmer M
    J Urol Nephrol (Paris); 1977 Sep; 83(9):735-8. PubMed ID: 926237
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
    Saltissi D; Sauvage D; Westhuyzen J
    Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
    Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
    Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
    Fishbane S; Lynn RI
    Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
    Auerbach M; Ballard H; Trout JR; McIlwain M; Ackerman A; Bahrain H; Balan S; Barker L; Rana J
    J Clin Oncol; 2004 Apr; 22(7):1301-7. PubMed ID: 15051778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia.
    Westad S; Backe B; Salvesen KA; Nakling J; Økland I; Borthen I; Rognerud Jensen OH; Kolås T; Løkvik B; Smedvig E
    Acta Obstet Gynecol Scand; 2008; 87(9):916-23. PubMed ID: 18720044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
    Ahsan N
    Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
    J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.
    Mystakidou K; Kalaidopoulou O; Katsouda E; Parpa E; Kouskouni E; Chondros C; Tsiatas ML; Vlahos L
    Anticancer Res; 2005; 25(5):3495-500. PubMed ID: 16101168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.